ZA200601321B - Ophtalmic compositions for treating ocular hypertension - Google Patents
Ophtalmic compositions for treating ocular hypertensionInfo
- Publication number
- ZA200601321B ZA200601321B ZA200601321A ZA200601321A ZA200601321B ZA 200601321 B ZA200601321 B ZA 200601321B ZA 200601321 A ZA200601321 A ZA 200601321A ZA 200601321 A ZA200601321 A ZA 200601321A ZA 200601321 B ZA200601321 B ZA 200601321B
- Authority
- ZA
- South Africa
- Prior art keywords
- sub
- ophtalmic
- compositions
- ocular hypertension
- sup
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010030043 Ocular hypertension Diseases 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 229940125422 potassium channel blocker Drugs 0.000 abstract 1
- 239000003450 potassium channel blocker Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
- C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50009503P | 2003-09-04 | 2003-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200601321B true ZA200601321B (en) | 2007-05-30 |
Family
ID=34312181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200601321A ZA200601321B (en) | 2003-09-04 | 2006-02-14 | Ophtalmic compositions for treating ocular hypertension |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7410992B2 (fr) |
| EP (1) | EP1663987B1 (fr) |
| JP (1) | JP4546961B2 (fr) |
| KR (1) | KR20060090801A (fr) |
| CN (2) | CN102558231B (fr) |
| AT (1) | ATE425971T1 (fr) |
| AU (1) | AU2004272546B2 (fr) |
| BR (1) | BRPI0414102A (fr) |
| CA (1) | CA2537410C (fr) |
| DE (1) | DE602004020079D1 (fr) |
| EC (1) | ECSP066404A (fr) |
| IL (1) | IL174068A0 (fr) |
| IS (1) | IS8306A (fr) |
| MA (1) | MA28017A1 (fr) |
| MX (1) | MXPA06002515A (fr) |
| NO (1) | NO20061505L (fr) |
| NZ (1) | NZ545401A (fr) |
| RU (1) | RU2006110625A (fr) |
| WO (1) | WO2005026128A1 (fr) |
| ZA (1) | ZA200601321B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1771170A4 (fr) * | 2004-07-20 | 2009-07-08 | Merck & Co Inc | Compositions ophtalmiques traitant l'hypertension oculaire |
| AU2011231544B2 (en) * | 2010-03-26 | 2015-01-15 | Galderma Research & Development | Improved methods and compositions for safe and effective treatment of telangiectasia |
| EP2626702A4 (fr) * | 2010-10-08 | 2014-03-26 | Axis Inc | Agent diagnostique, méthode diagnostique et agent thérapeutique pour traiter la fibromyalgie |
| WO2012139495A1 (fr) * | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | Antagonistes des récepteurs de minéralocorticoïdes |
| CN110256314B (zh) * | 2019-06-28 | 2020-12-15 | 南京林业大学 | 一种β-芳基酮类化合物的制备方法及其产品 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2534580A1 (fr) | 1982-10-13 | 1984-04-20 | Synthelabo | Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent |
| US5151444B1 (en) | 1987-09-18 | 1999-07-06 | R Tech Ueno Ltd | Ocular hypotensive agents |
| WO1989010757A1 (fr) | 1988-05-10 | 1989-11-16 | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis | Nouvelle preparation ophtalmique pour le traitement de glaucomes |
| ES2213504T1 (es) | 1988-09-06 | 2004-09-01 | Pfizer Health Ab | Derivados de prostaglandina para el tratamiento del glaucoma o hipertension ocular. |
| US5296504A (en) | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US5352708A (en) | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US5922773A (en) | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
| JPH08511024A (ja) | 1993-06-08 | 1996-11-19 | バイディ ファーマシューティカルズ | 眼内圧を低下させる方法および組成物 |
| US5510383A (en) | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
| US5573758A (en) | 1995-04-28 | 1996-11-12 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers |
| US5925342A (en) | 1996-11-13 | 1999-07-20 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers |
| EP1114816A4 (fr) | 1998-09-14 | 2002-09-04 | Ono Pharmaceutical Co | DERIVES E DE PHENYL-PROSTAGLANDINE A SUBSTITUTION-$g(V) ET MEDICAMENTS LES CONTENANT COMME INGREDIENT ACTIF |
| DE19846514A1 (de) * | 1998-10-09 | 2000-04-20 | Bayer Ag | Neue Heterocyclyl-methyl-substituierte Pyrazole |
| EE200200355A (et) | 1999-12-22 | 2003-10-15 | Pfizer Products Inc. | EP4 retseptori selektiivsed agonistid osteoporoosi raviks |
| CA2396319A1 (fr) * | 2000-01-18 | 2001-07-26 | Merck & Co., Inc. | Compositions ophthalmiques pour traiter l'hypertension oculaire |
| WO2001070702A1 (fr) | 2000-03-17 | 2001-09-27 | Alcon, Inc. | Derives de 6-hydroxy-indazole destines au traitement du glaucome |
| AU4466901A (en) | 2000-03-31 | 2001-10-08 | Toray Industries, Inc. | Hair growth or hair formation controlling agents |
| WO2002024647A1 (fr) | 2000-09-21 | 2002-03-28 | Ono Pharmaceutical Co., Ltd. | Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine |
| MXPA03004623A (es) | 2000-11-27 | 2003-09-05 | Pfizer Prod Inc | Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis. |
| US20050256117A1 (en) * | 2002-06-14 | 2005-11-17 | Meng Hsin Chen | Ophthalmic compositions for treating ocular hypertension |
| US7528163B2 (en) * | 2002-11-08 | 2009-05-05 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
| US7196082B2 (en) * | 2002-11-08 | 2007-03-27 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
| US7053085B2 (en) | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
| CN1842335A (zh) * | 2003-09-04 | 2006-10-04 | 默克公司 | 用于治疗高眼压的眼用组合物 |
-
2004
- 2004-08-31 EP EP04782695A patent/EP1663987B1/fr active Active
- 2004-08-31 CN CN201110399520.0A patent/CN102558231B/zh not_active Expired - Fee Related
- 2004-08-31 WO PCT/US2004/028266 patent/WO2005026128A1/fr active Application Filing
- 2004-08-31 CA CA002537410A patent/CA2537410C/fr not_active Expired - Fee Related
- 2004-08-31 US US10/569,921 patent/US7410992B2/en active Active
- 2004-08-31 JP JP2006525389A patent/JP4546961B2/ja not_active Expired - Fee Related
- 2004-08-31 BR BRPI0414102-4A patent/BRPI0414102A/pt not_active IP Right Cessation
- 2004-08-31 NZ NZ545401A patent/NZ545401A/en unknown
- 2004-08-31 CN CNA2004800253442A patent/CN1845904A/zh active Pending
- 2004-08-31 RU RU2006110625/04A patent/RU2006110625A/ru not_active Application Discontinuation
- 2004-08-31 AU AU2004272546A patent/AU2004272546B2/en not_active Ceased
- 2004-08-31 DE DE602004020079T patent/DE602004020079D1/de active Active
- 2004-08-31 AT AT04782695T patent/ATE425971T1/de not_active IP Right Cessation
- 2004-08-31 KR KR1020067004459A patent/KR20060090801A/ko not_active Application Discontinuation
- 2004-08-31 MX MXPA06002515A patent/MXPA06002515A/es not_active Application Discontinuation
-
2006
- 2006-02-14 ZA ZA200601321A patent/ZA200601321B/xx unknown
- 2006-02-16 IS IS8306A patent/IS8306A/is unknown
- 2006-03-01 MA MA28846A patent/MA28017A1/fr unknown
- 2006-03-01 EC EC2006006404A patent/ECSP066404A/es unknown
- 2006-03-02 IL IL174068A patent/IL174068A0/en unknown
- 2006-04-03 NO NO20061505A patent/NO20061505L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1663987B1 (fr) | 2009-03-18 |
| CN102558231B (zh) | 2015-05-27 |
| KR20060090801A (ko) | 2006-08-16 |
| CN102558231A (zh) | 2012-07-11 |
| WO2005026128A1 (fr) | 2005-03-24 |
| ECSP066404A (es) | 2006-09-18 |
| US7410992B2 (en) | 2008-08-12 |
| CN1845904A (zh) | 2006-10-11 |
| IL174068A0 (en) | 2006-08-01 |
| MXPA06002515A (es) | 2006-06-20 |
| ATE425971T1 (de) | 2009-04-15 |
| JP2007504233A (ja) | 2007-03-01 |
| AU2004272546B2 (en) | 2007-10-18 |
| AU2004272546A1 (en) | 2005-03-24 |
| EP1663987A1 (fr) | 2006-06-07 |
| US20070010491A1 (en) | 2007-01-11 |
| NO20061505L (no) | 2006-04-27 |
| IS8306A (is) | 2006-02-16 |
| JP4546961B2 (ja) | 2010-09-22 |
| NZ545401A (en) | 2008-10-31 |
| RU2006110625A (ru) | 2006-08-10 |
| DE602004020079D1 (de) | 2009-04-30 |
| CA2537410A1 (fr) | 2005-03-24 |
| BRPI0414102A (pt) | 2006-10-31 |
| MA28017A1 (fr) | 2006-07-03 |
| CA2537410C (fr) | 2009-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003207900A1 (en) | Methods of treatment with selective ep4 receptor agonists | |
| WO2006044425A3 (fr) | Compositions ophtalmiques de traitement de l'hypertension oculaire | |
| WO2005002520A3 (fr) | Compositions ophtalmiques destinees au traitement d'hypertension oculaire | |
| DE60309829D1 (de) | Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davon | |
| BR0014596A (pt) | Derivado de pirimidina, uso do mesmo, composição farmacêutica, e, método de tratar doenças ou condições médicas mediadas por citocinas | |
| ECSP055781A (es) | Composiciones oftálmicas para el tratamiento de la hipertensión ocular | |
| WO2005020917A3 (fr) | Compositions ophtalmiques pour le traitement de l'hypertension oculaire | |
| MX2007006504A (es) | Derivados de malonamida como inhibidores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer. | |
| ZA200601321B (en) | Ophtalmic compositions for treating ocular hypertension | |
| WO2007025897A3 (fr) | Derives de benzooxazole, oxazolopyridine, benzothiazole et thiazolopyridine | |
| WO2002009702A8 (fr) | Methode de reduction de la pression intraoculaire avec des derives d'indole | |
| DE69008142D1 (de) | 4-Substituierten Imidazolen zur Senkung des intraokularen Druckes. | |
| WO2004043354A3 (fr) | Compositions ophtalmiques pour traiter l'hypertension oculaire | |
| DE60003435D1 (de) | Neue 2-decarboxy-2-phosphinico prostaglandin f analoge | |
| WO2006020003A3 (fr) | Compositions ophtalmiques traitant l'hypertension oculaire | |
| WO2003057213A3 (fr) | Composes derives de cyclohexano- et cycloheptapyrazole destines au traitement des maladies associees au recepteur 5-ht2c | |
| ATE409491T1 (de) | Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension | |
| BR0314419A (pt) | Compostos de 5-croman-5-il-etilamina substituìdos, seu uso e composição farmacêutica incluindo-o | |
| IL166103A0 (en) | Pyrrolidine derivatives and their use | |
| MY129575A (en) | Methods, kits and compositions for using pyrrole derivatives againts anxiety | |
| WO2008030390A3 (fr) | Compositions ophtalmiques pour le traitement de l'hypertension oculaire | |
| TW200509889A (en) | Aniline derivatives | |
| WO2003077845A3 (fr) | Compositions et methodes de traitement du glaucome et de l'hypertension oculaire | |
| CA3156457A1 (fr) | Composes 1,8-naphtyridin-2-one pour le traitement d'une maladie auto-immune | |
| WO2004087051A3 (fr) | Compositions ophtalmiques pour traiter une hypertension oculaire |